ThermoGenesis Regains Compliance with Nasdaq Minimum Bid Price Requirement
RANCHO CORDOVA, Calif., Jan. 11, 2023 /PRNewswire/ — ThermoGenesis Holdings, Inc. (NASDAQ: THMO) (the “Company”), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq’s minimum bid price for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2) (“Min Bid Price Rule”).
Related news for (THMO)
- ThermoGenesis Holdings Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- ThermoGenesis Holdings Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- ThermoGenesis Holdings to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide a Corporate Strategic Update
- ThermoGenesis to Open a New 35,500 Square Foot ReadyStart-IncuStart cGMP Facility in Greater Sacramento
- ThermoGenesis Holdings to Present at the H.C. Wainwright 25th Annual Global Investment Conference